{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T03:05:01Z","timestamp":1766545501546},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s11894-006-0040-6","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T17:42:24Z","timestamp":1179596544000},"page":"499-505","source":"Crossref","is-referenced-by-count":8,"title":["Insights in immunomodulatory therapies for ulcerative colitis and Crohn\u2019s disease"],"prefix":"10.1007","volume":"8","author":[{"given":"Geoffrey C.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary L.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Themistocles","family":"Dassopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"40_CR1","first-page":"A110","volume":"130","author":"GR D\u2019Haens","year":"2006","unstructured":"D\u2019Haens GR, Hommes D, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn\u2019s disease. Gastroenterology 2006, 130:A110.","journal-title":"Gastroenterology"},{"key":"40_CR2","first-page":"A108","volume":"130","author":"D Hommes","year":"2006","unstructured":"Hommes D, Baert F, van Assche G, et al.: The ideal management of Crohn\u2019s disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology 2006, 130:A108.","journal-title":"Gastroenterology"},{"key":"40_CR3","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4049\/jimmunol.176.1.640","volume":"176","author":"D Poppe","year":"2006","unstructured":"Poppe D, Tiede I, Fritz G, et al.: Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006, 176:640\u201351.","journal-title":"J Immunol"},{"key":"40_CR4","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/j.gastro.2006.01.048","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940\u2013987.","journal-title":"Gastroenterology"},{"key":"40_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","volume":"55","author":"S Ardizzone","year":"2006","unstructured":"Ardizzone S, Maconi G, Russo A, et al.: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47\u201353. This study is an important and long-awaited trial with wellde fined endpoints that demonstrates the role of AZA in the maintenance of UC.","journal-title":"Gut"},{"key":"40_CR6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2004.06.002","volume":"127","author":"SB Hanauer","year":"2004","unstructured":"Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn\u2019s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723\u2013729.","journal-title":"Gastroenterology"},{"key":"40_CR7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2004.06.051","volume":"127","author":"S Ardizzone","year":"2004","unstructured":"Ardizzone S, Maconi G, Sampietro GM, et al.: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn\u2019s disease. Gastroenterology 2004, 127:730\u2013740.","journal-title":"Gastroenterology"},{"key":"40_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2004.045294","volume":"54","author":"J Cosnes","year":"2005","unstructured":"Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn\u2019s disease on the need for intestinal surgery. Gut 2005, 54:237\u2013241.","journal-title":"Gut"},{"key":"40_CR9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1542-3565(04)00344-1","volume":"2","author":"MC Dubinsky","year":"2004","unstructured":"Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004, 2:731\u2013743. This article provides an excellent review of AZA metabolism and optimization of thiopurine therapy.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"40_CR10","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2006.01.047","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:935\u2013939.","journal-title":"Gastroenterology"},{"key":"40_CR11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1542-3565(04)00127-2","volume":"2","author":"C Cuffari","year":"2004","unstructured":"Cuffari C, Dassopoulos T, Turnbough L, et al.: Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004, 2:410\u2013417. This study provides novel insight into the role of TPMT in the clinical response to the thiopurines.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"40_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2036.2005.02583.x","volume":"22","author":"MP Sparrow","year":"2005","unstructured":"Sparrow MP, Hande SA, Friedman S, et al.: Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22:441\u2013446.","journal-title":"Aliment Pharmacol Ther"},{"key":"40_CR13","first-page":"A142","volume":"130","author":"M Sparrow","year":"2006","unstructured":"Sparrow M, Hande SA, Friedman S, et al.: Optimization of 6-thioguanine production by allopurinol in inflammatory bowel disease patients not responding to azathioprine\/6-mercaptopurine leads to improved disease activity, reduced corticosteroid requirements and normalization of liver enzymes. Gastroenterology 2006, 130:A142.","journal-title":"Gastroenterology"},{"key":"40_CR14","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/00365520510023369","volume":"40","author":"A Teml","year":"2005","unstructured":"Teml A, Schwab M, Harrer M, et al.: A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol 2005, 40:1205\u20131213.","journal-title":"Scand J Gastroenterol"},{"key":"40_CR15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0016-5085(03)00938-7","volume":"125","author":"MC Dubinsky","year":"2003","unstructured":"Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298\u2013303.","journal-title":"Gastroenterology"},{"key":"40_CR16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","volume":"130","author":"MT Osterman","year":"2006","unstructured":"Osterman MT, Kundu R, Lichtenstein GR, et al.: Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047\u20131053.","journal-title":"Gastroenterology"},{"key":"40_CR17","first-page":"A84","volume":"130","author":"MF Neurath","year":"2006","unstructured":"Neurath MF, Kiesslich R, Teichgraeber U, et al.: Prediction of azathioprine responsiveness in Crohn\u2019s disease by 6-thioguanosine di- and triphosphate levels in red blood cells: a prospective study. Gastroenterology 2006, 130:A84.","journal-title":"Gastroenterology"},{"key":"40_CR18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","volume":"128","author":"M Lemann","year":"2005","unstructured":"Lemann M, Mary JY, Colombel JF, et al.: A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812\u20131818. This important study demonstrates the advantage of continuing AZA maintenance therapy beyond 3.5 years of remission and has significant implications for clinical practice.","journal-title":"Gastroenterology"},{"key":"40_CR19","doi-asserted-by":"crossref","unstructured":"Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn\u2019s disease. Cochrane Database Syst Rev 2005, CD003459.","DOI":"10.1002\/14651858.CD003459.pub2"},{"key":"40_CR20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","volume":"35","author":"S Ardizzone","year":"2003","unstructured":"Ardizzone S, Bollani S, Manzionna G, et al.: Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn\u2019s disease: a randomised, investigatorblind study. Dig Liver Dis 2003, 35:619\u2013627.","journal-title":"Dig Liver Dis"},{"key":"40_CR21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.MIB.0000209787.19952.53","volume":"12","author":"JM Dieren van","year":"2006","unstructured":"van DierenJM, Kuipers EJ, Samsom JN, et al.: Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006, 12:311\u2013327.","journal-title":"Inflamm Bowel Dis"},{"key":"40_CR22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/01.fpc.0000172242.19675.33","volume":"15","author":"KR Herrlinger","year":"2005","unstructured":"Herrlinger KR, Cummings JR, Barnardo MC, et al.: The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005, 15:705\u2013711.","journal-title":"Pharmacogenet Genomics"},{"key":"40_CR23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","volume":"13","author":"SL Schreiber","year":"1992","unstructured":"Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136\u2013142.","journal-title":"Immunol Today"},{"key":"40_CR24","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","volume":"330","author":"S Lichtiger","year":"1994","unstructured":"Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841\u20131845.","journal-title":"N Engl J Med"},{"key":"40_CR25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1053\/gast.2001.23983","volume":"120","author":"G D\u2019Haens","year":"2001","unstructured":"D\u2019Haens G, Lemmens L, Geboes K, et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001, 120:1323\u20131329.","journal-title":"Gastroenterology"},{"key":"40_CR26","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","volume":"125","author":"G Assche van","year":"2003","unstructured":"van AsscheG, D\u2019Haens G, Noman M, et al.: Randomized, double-blind comparison of 4 mg\/kg versus 2 mg\/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125:1025\u20131031. This paper provides evidence supporting the efficacy of lower doses and target ranges for cyclosporine and has high clinical impact.","journal-title":"Gastroenterology"},{"key":"40_CR27","doi-asserted-by":"crossref","unstructured":"McDonald JW, Feagan BG, Jewell D, et al.: Cyclosporine for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2005, CD000297.","DOI":"10.1002\/14651858.CD000297.pub2"},{"key":"40_CR28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","volume":"55","author":"H Ogata","year":"2006","unstructured":"Ogata H, Matsui T, Nakamura M, et al.: A randomised, dose-finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255\u20131262.","journal-title":"Gut"},{"key":"40_CR29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0016-5085(03)00877-1","volume":"125","author":"WJ Sandborn","year":"2003","unstructured":"Sandborn WJ, Present DH, Isaacs KL, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn\u2019s disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380\u2013388.","journal-title":"Gastroenterology"},{"key":"40_CR30","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1572-0241.2006.00524.x","volume":"101","author":"DC Baumgart","year":"2006","unstructured":"Baumgart DC, Pintof. JP, Sturm A, et al.: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: a longterm follow-up. Am J Gastroenterol 2006, 101:1048\u20131056.","journal-title":"Am J Gastroenterol"},{"key":"40_CR31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gut.44.5.625","volume":"44","author":"MF Neurath","year":"1999","unstructured":"Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn\u2019s disease. Gut 1999, 44:625\u2013628.","journal-title":"Gut"},{"key":"40_CR32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1572-0241.2000.02010.x","volume":"95","author":"T Orth","year":"2000","unstructured":"Orth T, Peters M, Schlaak JF, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201\u20131207.","journal-title":"Am J Gastroenterol"},{"key":"40_CR33","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","volume":"124","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial. Gastroenterology 2003, 124:917\u2013924.","journal-title":"Gastroenterology"},{"key":"40_CR34","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1053\/j.gastro.2006.02.014","volume":"130","author":"M Lemann","year":"2006","unstructured":"Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn\u2019s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054\u20131061.","journal-title":"Gastroenterology"},{"key":"40_CR35","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al., for theACCENT I Study Group: Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541\u20131549.","journal-title":"Lancet"},{"key":"40_CR36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","volume":"50","author":"RN Maini","year":"2004","unstructured":"Maini RN, Breedveld FC, Kalden JR, et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051\u20131065.","journal-title":"Arthritis Rheum"},{"key":"40_CR37","first-page":"A142","volume":"130","author":"G Assche van","year":"2006","unstructured":"van AsscheG, Paintaud G, D\u2019 HG, et al.: Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn\u2019s disease but may improve pharmacokinetics. Gastroenterology 2006, 130:A142.","journal-title":"Gastroenterology"},{"key":"40_CR38","first-page":"A479","volume":"130","author":"R Panaccione","year":"2006","unstructured":"Panaccione R, Hanauer SB, Fedorak R, et al.: Concomitant immunosuppressive and adalimumab therapy in patients with Crohn\u2019s disease. Gastroenterology 2006, 130:A479.","journal-title":"Gastroenterology"},{"key":"40_CR39","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1572-0241.2004.11481.x","volume":"99","author":"GJ Mantzaris","year":"2004","unstructured":"Mantzaris GJ, Sfakianakis M, Archavlis E, et al.: A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004, 99:1122\u20131128.","journal-title":"Am J Gastroenterol"},{"key":"40_CR40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/01.MIB.0000206544.05661.9f","volume":"12","author":"S Hande","year":"2006","unstructured":"Hande S, Wilson-Rich N, Bousvaros A, et al.: 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006, 12:251\u2013257.","journal-title":"Inflamm Bowel Dis"},{"key":"40_CR41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","volume":"54","author":"A Kandiel","year":"2005","unstructured":"Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121\u20131125.","journal-title":"Gut"},{"key":"40_CR42","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cgh.2006.03.018","volume":"4","author":"W Disanti","year":"2006","unstructured":"Disanti W, Rajapakse RO, Korelitz BI, et al.: Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:1025\u20131029.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"40_CR43","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","volume":"118","author":"JD Lewis","year":"2000","unstructured":"Lewis JD, Schwartz JS, Lichtenstein GR: Azathioprine for maintenance of remission in Crohn\u2019s disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118:1018\u201324.","journal-title":"Gastroenterology"},{"key":"40_CR44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/1042819021000035662","volume":"44","author":"JT Navarro","year":"2003","unstructured":"Navarro JT, Ribera JM, Mate JL, et al.: Hepatosplenic T-gammadelta lymphoma in a patient with Crohn\u2019s disease treated with azathioprine. Leuk Lymphoma 2003, 44:531\u2013533.","journal-title":"Leuk Lymphoma"},{"key":"40_CR45","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005176-200502000-00026","volume":"40","author":"M Thayu","year":"2005","unstructured":"Thayu M, Markowitz JE, Mamula P, et al.: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005, 40:220\u2013222.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"40_CR46","first-page":"A71","volume":"130","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Cohen RD, Feagan BG, et al.: Safety of infliximab and other Crohn\u2019s disease therapies \u2014 TREAT registry data with nearly 15,000 patient-years of follow-up. Gastroenterology 2006, 130, 4(Supp 2):A71.","journal-title":"Gastroenterology"},{"key":"40_CR47","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1053\/S0016-5085(05)02501-1","volume":"130","author":"SV Kane","year":"2006","unstructured":"Kane SV, Khatibi B, Reddy D: Use of immunosuppressants results in a higher incidence of abnormal Pap smears in women with inflammatory bowel disease (IBD). Gastroenterology 2006, 130:A2.","journal-title":"Gastroenterology"},{"key":"40_CR48","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","volume":"99","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV, Jr, Tremaine WJ, et al.: Early postoperative complications are not increased in patients with Crohn\u2019s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004, 99:878\u2013883.","journal-title":"Am J Gastroenterol"},{"key":"40_CR49","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/bjs.5375","volume":"93","author":"V Subramanian","year":"2006","unstructured":"Subramanian V, Pollok RC, Kang JY, et al.: Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006, 93:793\u2013799.","journal-title":"Br J Surg"},{"key":"40_CR50","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1046\/j.1365-2036.2003.01537.x","volume":"17","author":"B Norgard","year":"2003","unstructured":"Norgard B, Pedersen L, Fonager K, et al.: Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003, 17:827\u2013834.","journal-title":"Aliment Pharmacol Ther"},{"key":"40_CR51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/gast.2003.50014","volume":"124","author":"A Francella","year":"2003","unstructured":"Francella A, Dyan A, Bodian C, et al.: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124:9\u201317. This paper describes the largest series of pregnant women with IBD who have undergone 6-MP therapy","journal-title":"Gastroenterology"},{"key":"40_CR52","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","volume":"71","author":"OB Bar","year":"2001","unstructured":"Bar OB, Hackman R, Einarson T, et al.: Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001, 71:1051\u20131055.","journal-title":"Transplantation"},{"key":"40_CR53","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1136\/gut.2005.078972","volume":"54","author":"DC Baumgart","year":"2005","unstructured":"Baumgart DC, Sturm A, Wiedenmann B, et al.: Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005, 54:1822\u20131823","journal-title":"Gut"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-006-0040-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-006-0040-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-006-0040-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:03:56Z","timestamp":1559419436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-006-0040-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["40"],"URL":"https:\/\/doi.org\/10.1007\/s11894-006-0040-6","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}